Selected Prior Publications by AGADA team:

1.      Aoki Y, Yokota T, Nagata T, Nakamura A, Tanihata J, Saito T, Duguez SM, Nagaraju K, Hoffman EP, Partridge T, Takeda S (2012) Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci U S A 109: 13763-13768


2.      Baudy AR, Reeves EK, Damsker JM, Heier C, Garvin LM, Dillingham BC, McCall J, Rayavarapu S, Wang Z, Vandermeulen JH, Sali A, Jahnke V, Duguez S, DuBois D, Rose MC, Nagaraju K, Hoffman EP (2012) Delta-9,11 modification of glucocorticoids dissociates nuclear factor-kappaB inhibitory efficacy from glucocorticoid response element-associated side effects. J Pharmacol Exp Ther 343: 225-232


3.      Brown KJ, Marathi R, Fiorillo AA, Ciccimaro EF, Sharma S, Rowlands DS, Rayavarapu S, Nagaraju K, Hoffman EP, Hathout Y (2012) Accurate Quantitation of Dystrophin Protein in Human Skeletal Muscle Using Mass Spectrometry. Journal of bioanalysis & biomedicine Suppl 7


4.      Coley W, Rayavarapu S, van der Meulen JH, Duba AS, Nagaraju K (2013) Daily supplementation of D-ribose shows no therapeutic benefits in the MHC-I transgenic mouse model of inflammatory myositis. PLoS One 8: e65970


5.      Damsker JM, Dillingham BC, Rose MC, Balsley MA, Heier CR, Watson AM, Stemmy EJ, Jurjus RA, Huynh T, Tatem K, Uaesoontrachoon K, Berry DM, Benton AS, Freishtat RJ, Hoffman EP, McCall JM, Gordish-Dressman H, Constant SL, Reeves EK, Nagaraju K (2013) VBP15, a glucocorticoid analogue, is effective at reducing allergic lung inflammation in mice. PLoS One 8: e63871


6.      Heier CR, Damsker JM, Yu Q, Dillingham BC, Huynh T, Van der Meulen JH, Sali A, Miller BK, Phadke A, Scheffer L, Quinn J, Tatem K, Jordan S, Dadgar S, Rodriguez OC, Albanese C, Calhoun M, Gordish-Dressman H, Jaiswal JK, Connor EM, McCall JM, Hoffman EP, Reeves EK, Nagaraju K (2013) VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol Med 5: 1569-1585


7.      Huynh T, Uaesoontrachoon K, Quinn JL, Tatem KS, Heier CR, Van Der Meulen JH, Yu Q, Harris M, Nolan CJ, Haegeman G, Grounds MD, Nagaraju K (2013) Selective modulation through the glucocorticoid receptor ameliorates muscle pathology in mdx mice. J Pathol 231: 223-235


8.      Jahnke VE, Van Der Meulen JH, Johnston HK, Ghimbovschi S, Partridge T, Hoffman EP, Nagaraju K (2012) Metabolic remodeling agents show beneficial effects in the dystrophin-deficient mdx mouse model. Skelet Muscle 2: 16


9.      Kostek MC, Nagaraju K, Pistilli E, Sali A, Lai SH, Gordon B, Chen YW (2012) IL-6 signaling blockade increases inflammation but does not affect muscle function in the mdx mouse. BMC Musculoskelet Disord 13: 106


10.     Quinn JL, Huynh T, Uaesoontrachoon K, Tatem K, Phadke A, Van der Meulen JH, Yu Q, Nagaraju K (2013) Effects of Dantrolene Therapy on Disease Phenotype in Dystrophin Deficient mdx Mice. PLoS currents 5


11.      Rayavarapu S, Coley W, Cakir E, Jahnke V, Takeda S, Aoki Y, Grodish-Dressman H, Jaiswal JK, Hoffman EP, Brown KJ, Hathout Y, Nagaraju K (2013a) Identification of disease specific pathways using in vivo SILAC proteomics in dystrophin deficient mdx mouse. Molecular & cellular proteomics : MCP 12: 1061-1073


12.      Rayavarapu S, Coley W, Van der Meulen JH, Cakir E, Tappeta K, Kinder TB, Dillingham BC, Brown KJ, Hathout Y, Nagaraju K (2013b) Activation of the ubiquitin proteasome pathway in a mouse model of inflammatory myopathy: a potential therapeutic target. Arthritis Rheum 65: 3248-3258


13.      Reeves EK, Hoffman EP, Nagaraju K, Damsker JM, McCall JM (2013) VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid. Bioorg Med Chem 21: 2241-2249


14.      Sali A, Guerron AD, Gordish-Dressman H, Spurney CF, Iantorno M, Hoffman EP, Nagaraju K (2012) Glucocorticoid-treated mice are an inappropriate positive control for long-term preclinical studies in the mdx mouse. PLoS One 7: e34204


15.      Sali A, Many GM, Gordish-Dressman H, van der Meulen JH, Phadke A, Spurney CF, Cnaan A, Hoffman EP, Nagaraju K (2013) The proton pump inhibitor lansoprazole improves the skeletal phenotype in dystrophin deficient mdx mice. PLoS One 8: e66617


16.      Spurney C, Yu Q, Nagaraju K (2011) Speckle tracking analysis of the left ventricular anterior wall shows significantly decreased relative radial strain patterns in dystrophin deficient mice after 9 months of age. PLoS currents 3: RRN1273


17.      Uaesoontrachoon K, Cha HJ, Ampong B, Sali A, Vandermeulen J, Wei B, Creeden B, Huynh T, Quinn J, Tatem K, Rayavarapu S, Hoffman EP, Nagaraju K (2013) The effects of MyD88 deficiency on disease phenotype in dysferlin-deficient A/J mice: role of endogenous TLR ligands. J Pathol 231: 199-209


18.      Uaesoontrachoon K, Quinn JL, Tatem KS, Van Der Meulen JH, Yu Q, Phadke A, Miller BK, Gordish-Dressman H, Ongini E, Miglietta D, Nagaraju K (2014) Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy. Hum Mol Genet


19.      Willmann R, De Luca A, Benatar M, Grounds M, Dubach J, Raymackers JM, Nagaraju K, Network T-NN (2012) Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice. Neuromuscul Disord 22: 43-49


20.      Yu Q, Sali A, Van der Meulen J, Creeden BK, Gordish-Dressman H, Rutkowski A, Rayavarapu S, Uaesoontrachoon K, Huynh T, Nagaraju K, Spurney CF (2013) Omigapil Treatment Decreases Fibrosis and Improves Respiratory Rate in dy(2J) Mouse Model of Congenital Muscular Dystrophy. PLoS One 8: e65468


For more publications, please visit the following pubmed links:


Professor Kanneboyina Nagaraju: Pubmed


Professor Eric P Hoffman: Pubmed


Dr. Kitipong Uaesoontrachoon: Pubmed

Print Print | Sitemap
© AGADA Biosciences